Treatment of rhegmatogenous retinal detachment: from the past to the future

Rhegmatogenous retinal detachment (RRD) is a severe disorder that can potentially lead to blindness. The traction developing in pathological attachment of the vitreous to retinal degeneration areas and in posterior hyaloid detachment leads to formation of retinal breaks and subsequent retinal detach...

Full description

Bibliographic Details
Main Authors: M. Iu. Krongauz, I.O. Nasinnyk, N.V. Pasyechnikova
Format: Article
Language:English
Published: Ukrainian Society of Ophthalmologists 2020-02-01
Series:Journal of Ophthalmology
Subjects:
Online Access:https://www.ozhurnal.com/en/archive/2020/1/8-fulltext
_version_ 1797387593699033088
author M. Iu. Krongauz
I.O. Nasinnyk
N.V. Pasyechnikova
author_facet M. Iu. Krongauz
I.O. Nasinnyk
N.V. Pasyechnikova
author_sort M. Iu. Krongauz
collection DOAJ
description Rhegmatogenous retinal detachment (RRD) is a severe disorder that can potentially lead to blindness. The traction developing in pathological attachment of the vitreous to retinal degeneration areas and in posterior hyaloid detachment leads to formation of retinal breaks and subsequent retinal detachment. The approach to treatment of RRD has changed with years from cautery (J. Gonin, 1920) to modern vitrectomy (R. Machemer, 1973). Current advances in vitrectomy are related mostly to the three major fields: development of advanced vitrectomy tools, novel operative techniques and tamponade agents. The tamponade agents used in vitrectomy have specific advantages and disadvantages. Therefore, new solutions are being sought to minimize harmful effects of tamponade agents on ocular tissues, which would make the process of rehabilitation more comfortable for patients. In recent decades, the potential for using hydrogels as a substitute to the vitreous removed during vitrectomy has been actively explored (Widder, 1960, Balazs, 1972, Malson, 1985). The first commercially available biomedical sodium hyaluronate product for use in eye surgery, Healon, was developed by Balazs. Although Healon was developed as a vitreous substitute, it has been successfully used also in cataract surgery, and truly initiated the age of viscosurgery. The research on the potential for using hydrogels as a visual substitute is underway.
first_indexed 2024-03-08T22:28:21Z
format Article
id doaj.art-722b2431cf984edea9de975054e65f0c
institution Directory Open Access Journal
issn 2412-8740
language English
last_indexed 2024-03-08T22:28:21Z
publishDate 2020-02-01
publisher Ukrainian Society of Ophthalmologists
record_format Article
series Journal of Ophthalmology
spelling doaj.art-722b2431cf984edea9de975054e65f0c2023-12-18T09:07:59ZengUkrainian Society of OphthalmologistsJournal of Ophthalmology2412-87402020-02-011404810.31288/oftalmolzh202014048Treatment of rhegmatogenous retinal detachment: from the past to the futureM. Iu. Krongauz0I.O. Nasinnyk1N.V. Pasyechnikova2Filatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical Science of UkraineFilatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical Science of UkraineFilatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical Science of UkraineRhegmatogenous retinal detachment (RRD) is a severe disorder that can potentially lead to blindness. The traction developing in pathological attachment of the vitreous to retinal degeneration areas and in posterior hyaloid detachment leads to formation of retinal breaks and subsequent retinal detachment. The approach to treatment of RRD has changed with years from cautery (J. Gonin, 1920) to modern vitrectomy (R. Machemer, 1973). Current advances in vitrectomy are related mostly to the three major fields: development of advanced vitrectomy tools, novel operative techniques and tamponade agents. The tamponade agents used in vitrectomy have specific advantages and disadvantages. Therefore, new solutions are being sought to minimize harmful effects of tamponade agents on ocular tissues, which would make the process of rehabilitation more comfortable for patients. In recent decades, the potential for using hydrogels as a substitute to the vitreous removed during vitrectomy has been actively explored (Widder, 1960, Balazs, 1972, Malson, 1985). The first commercially available biomedical sodium hyaluronate product for use in eye surgery, Healon, was developed by Balazs. Although Healon was developed as a vitreous substitute, it has been successfully used also in cataract surgery, and truly initiated the age of viscosurgery. The research on the potential for using hydrogels as a visual substitute is underway. https://www.ozhurnal.com/en/archive/2020/1/8-fulltextvitrectomysilicone oilgas tamponaderhegmatogenous retinal detachmenthydrogelviscosurgery
spellingShingle M. Iu. Krongauz
I.O. Nasinnyk
N.V. Pasyechnikova
Treatment of rhegmatogenous retinal detachment: from the past to the future
Journal of Ophthalmology
vitrectomy
silicone oil
gas tamponade
rhegmatogenous retinal detachment
hydrogel
viscosurgery
title Treatment of rhegmatogenous retinal detachment: from the past to the future
title_full Treatment of rhegmatogenous retinal detachment: from the past to the future
title_fullStr Treatment of rhegmatogenous retinal detachment: from the past to the future
title_full_unstemmed Treatment of rhegmatogenous retinal detachment: from the past to the future
title_short Treatment of rhegmatogenous retinal detachment: from the past to the future
title_sort treatment of rhegmatogenous retinal detachment from the past to the future
topic vitrectomy
silicone oil
gas tamponade
rhegmatogenous retinal detachment
hydrogel
viscosurgery
url https://www.ozhurnal.com/en/archive/2020/1/8-fulltext
work_keys_str_mv AT miukrongauz treatmentofrhegmatogenousretinaldetachmentfromthepasttothefuture
AT ionasinnyk treatmentofrhegmatogenousretinaldetachmentfromthepasttothefuture
AT nvpasyechnikova treatmentofrhegmatogenousretinaldetachmentfromthepasttothefuture